Evidence map›Paper›PMID 38496546›Full record

ArticlebioRxiv : the preprint server for biology2024

CD47 is Required for Mesenchymal Progenitor Proliferation and Fracture Repair.

Robert L Zondervan, Christina A Capobianco, Daniel C Jenkins, John D Reicha, Livia M Fredrick, Charles Lam, Jeffery S Isenberg, Jaimo Ahn, Ralph S Marcucio, Kurt D Hankenson

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Robert L ZondervanDepartment of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, United States, 48109.ORCID 0000-0002-0825-4684
Christina A CapobiancoDepartment of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, United States, 48109.ORCID 0000-0003-0191-7606
Daniel C JenkinsDepartment of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, United States, 48109.ORCID 0000-0003-1966-1645
John D ReichaDepartment of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, United States, 48109.
Livia M FredrickDepartment of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, United States, 48109.
Charles LamDepartment of Orthopaedic Surgery, University of California at San Francisco, San Francisco, California, United States, 94142.
Jeffery S IsenbergDepartment of Diabetes Complications and Metabolism and Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope National Medical Center, Duarte, California, United States, 91010.ORCID 0000-0002-4221-1688
Jaimo AhnDepartment of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, United States, 48109.ORCID 0000-0001-8151-9987
Ralph S MarcucioDepartment of Orthopaedic Surgery, University of California at San Francisco, San Francisco, California, United States, 94142.ORCID 0000-0002-0537-818X
Kurt D HankensonDepartment of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, United States, 48109.ORCID 0000-0001-6361-143X
University of Michigan · USUniversity of California, San Francisco · USCity Of Hope National Medical Center · US

Funding

Regulators of Ischemic Fracture HealingR01AR066028 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HANKENSON, KURT DAVID · 2015 to 2020
$2.7M
CTSA Predoctoral T32 at the University of MichiganT32TR004371 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI VICKI L ELLINGROD, MICHAEL Allan HOLINSTAT · 2023 to 2026
$2.2M
Disruption of CD47 signaling promotes healing in ischemic fractures and bone allograftsF30AR071201 · NIAMS · MICHIGAN STATE UNIVERSITY · PI ZONDERVAN, ROBERT LOUIS · 2017 to 2019
$126k
NCATS NIH HHS T32 TR004371NIAMS NIH HHS F30 AR071201NIAMS NIH HHS R01 AR066028
6 · The paper itself

Abstract

CD47 is a ubiquitous and pleiotropic cell-surface receptor. Disrupting CD47 enhances injury repair in various tissues but the role of CD47 has not been studied in bone injuries. In a murine closed-fracture model, CD47-null mice showed decreased callus bone volume, bone mineral content, and tissue mineral content as assessed by microcomputed tomography 10 days post-fracture, and increased fibrous volume as determined by histology. To understand the cellular basis for this phenotype, mesenchymal progenitors (MSC) were harvested from bone marrow. CD47-null MSC showed decreased large fibroblast colony formation (CFU-F), significantly less proliferation, and fewer cells in S-phase, although osteoblast differentiation was unaffected. However, consistent with prior research, CD47-null endothelial cells showed increased proliferation relative to WT cells. Similarly, in a murine ischemic fracture model, CD47-null mice showed reduced fracture callus bone volume and bone mineral content relative to WT. Consistent with our

Indexed as

angiogenesiscallusCD47fracture healingMesenchymal progenitor cell

Identifiers

PMID38496546
PMCPMC10942414
OpenAlexW4392613407

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.